2014/12/23: Cosmo Pharmaceuticals S.p.A.

Cosmo announces that all items on the agenda were approved at the Extraordinary Shareholders Meeting of December 22, 2014

Cosmo Pharmaceuticals S.p.A. announced that at the Extraordinary Shareholders’ Meeting called on December 22, 2014, 8’968’250 votes of the total 14’225’600 voting shares were present and shareholders approved the proposed capital reduction and board compensation as follows...


2014/12/08: Sygnis AG

SYGNIS AG signs initial non-exclusive distribution agreement for its first proprietary product with BioCat GmbH

SYGNIS AG today announced that it has signed an initial distribution agreement for its first proprietary product with German BioCat GmbH.


2014/11/19: Sygnis AG 

GBC  Research  reiterates  “BUY”  recommendation  for  SYGNIS  shares  with price target of €4.05

GBC  Research,  a German independent research house focusing on listed small and midcap companies, has published  a  research  update  on  the  DNA  amplification  and  sequencing  tools  company SYGNIS  AG.

2014/11/17: Sygnis AG 

Edison publishes research update on SYGNIS AG

Edison Investment Research  Limited,  has  published  a  research  update  on  the  DNA  amplification  and sequencing  tools  company  SYGNIS  AG.

2014/11/14: Cosmo Pharmaceuticals S.p.A.

Cosmo announces approval by Extraordinary Shareholders Meeting of November 14, 2014 of all items on the agenda

With regards to the Extraordinary Shareholders’ Meeting called on November 14, 2014 in order to resolve, among other items, the transfer of the registered office to Luxembourg, the Company informs that shareholders representing n. 10.288.273 shares on a voting share capital of n. 14.225.600 shares attended the Meeting; and that the Meeting has approved all items on the agenda, as follows...

2014/11/13: Sygnis AG 

SYGNIS AG plans rights offering

SYGNIS AG announced  that  the  Management Board of SYGNIS today resolved with the approval of the Supervisory Board to increase the Company’s share capital by up to EUR 2,475,678.00 by issue of up to 2,475,678 new shares.

2014/10/28: Apogenix GmbH

Positive  Results  from  APG101  Phase  II  Clinical  Trial Published in Clinical Cancer Research

Apogenix,  a  clinical  stage  biopharmaceutical company, announced today that the final data of the completed phase II clinical trial with APG101 in recurrent glioblastoma has been published in the peer-reviewed journal Clinical Cancer Research.


2014/10/20: Cosmo Pharmaceuticals S.p.A.

CORTIMENT® MMX®, a new treatment for Ulcerative Colitis, receives European approval

Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that Ferring’s CORTIMENT® MMX® (budesonide) treatment for the induction of remission in patients with active, mild to moderate Ulcerative Colitis has received marketing approval from 27 European Union member states following the EU Mutual Recognition Procedure (MRP).


2014/10/16: Cosmo Pharmaceuticals S.p.A.

Key Cosmo shareholders announce that they support the change of seat and will not tender shares

Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that Cosmo Holding & Management Group, dievini Hopp biotech GmbH & Co KG and the Heinrich Herz AG/Logistable Group, which together control 65.8% of the issued shares, have indicated their approval of the change of seat and that they will not make use of the right to put shares back to the Company.


2014/10/15: WILEX AG

WILEX publishes 9-month Financial Report 2014

WILEX AG (ISIN DE000A11QVV0 / WL6 / FWB) today published its financial report on the first nine months of 2014 (1 December 2013 – 31 August 2014).


2014/10/15: Cosmo Pharmaceuticals S.p.A.

Cosmo shareholders to vote on change of registered office and seat of management

Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that the board of directors has resolved to call an extraordinary shareholders meeting in order to propose a change of registered office and seat of management of the Company.


2014/10/14: WILEX AG

WILEX subsidiary Heidelberg Pharma extends research collaboration with Roche

WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that WILEX subsidiary Heidelberg Pharma and Roche extended the existing 2013 licence agreement to apply the antibody drug conjugate (ADC) technology for the further development of Roche antibodies.


2014/10/14: immatics GmbH

EU-funded consortium led by immatics and BioNTech to advance a novel class of fully personalized therapeutic cancer vaccines into clinical trials for brain cancer

immatics biotechnologies  GmbH  and BioNTech  AG announce today that they are moving a novel concept of fully personalized therapeutic cancer vaccines, Glioma Actively Personalized VAccine Consortium (GAPVAC), into the clinic.

2014/10/08: Cosmo Pharmaceuticals S.p.A.

Uceris® patent protection extended from 2020 until 2031

Cosmo Pharmaceuticals S.p.A. (SIX: COPN) announced that the US Patent Office had issued the notice of allowance of its patent application 13/226,758 for Uceris®.


2014/10/03: Cosmo Pharmaceuticals S.p.A.

Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement

Salix Pharmaceuticals, Ltd. (“Salix”) (NASDAQ: SLXP) and Cosmo Pharmaceuticals S.p.A. (“Cosmo”) (SIX: COPN) today announced that they have agreed to terminate their previously-announced merger agreement pursuant to which Salix would have combined with, and become a wholly-owned subsidiary of, Cosmo Technologies Limited, a subsidiary of Cosmo.  Under the terms of the termination, which is effective immediately, Salix will make a $25 million payment to Cosmo.

2014/09/23: Novaliq GmbH

Novaliq GmbH reports positive results from CyclASol ®  (Cyclosporine A solution) eye drops repeated and ascending dose Phase 1 study

CyclASol® (cyclosporine A solution formulation in the semi-fluorinated alkane vehicle F4H5) eye drops are safe and well tolerated
CyclASol® is th